ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHIV postexposure prophylaxis (PEP) is the only intervention for reducing HIV acquisition risk after exposure. Our objective was to describe PEP user characteristics and analyze national trends in PEP regimens recommended by the Centers for Disease Control and Prevention (CDC) in 2016 and of off-label bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for PEP.
methodsWe analyzed the IQVIA Real World Data-Longitudinal Prescriptions database to identify persons aged ≥16 years prescribed antiretroviral (ARV) PEP regimens recommended by CDC or BIC/FTC/TAF from 2015 to 2023. We excluded persons with an HIV diagnosis or prescribed ARVs for HIV or hepatitis B virus treatment. Two clinicians reviewed regimens to confirm probable PEP prescriptions. We reported an annual number of PEP users, stratified by demographic characteristics, regimen type, and days of supply.
resultsThe number of persons prescribed PEP increased from 20 618 in 2015 to 44 934 in 2023. The number of persons prescribed a bictegravir-based PEP regimen increased from 1377 (4.1% of total PEP users) in 2018 to 7536 (16.8%) in 2023. Among 44 934 PEP users in 2023, 53.8% were men, and 39.8% were aged 25-34 years. Most (88.4%) PEP users were prescribed a full course of PEP (28-30-day supply).
conclusionsOur analysis found an increasing trend in PEP use annually, possibly reflecting greater PEP awareness and broader HIV prevention efforts. Increased use of a bictegravir-based PEP regimen in 2023 suggests a shift in PEP prescribing practices, likely due to its once-daily dosing and high tolerability. Our findings can guide future recommendations for PEP medications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.